Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis
Abstract Background Nonadherence to disease-modifying drugs (DMDs) for multiple sclerosis (MS) is associated with poorer clinical outcomes, including higher rates of relapse and disease progression, and higher medical resource use. A systematic review and quantification of adherence and persistence...
Main Authors: | Jacqueline A. Nicholas, Natalie C. Edwards, Roger A. Edwards, Anna Dellarole, Megan Grosso, Amy L. Phillips |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12883-020-01830-0 |
Similar Items
-
Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
by: Pelayo Nieto-Gómez, et al.
Published: (2023-09-01) -
USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
by: V. R. Mkrtchyan, et al.
Published: (2016-12-01) -
Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis
by: María José Zarzuelo Romero, et al.
Published: (2021-04-01) -
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
by: Silvia Delgado, et al.
Published: (2021-02-01) -
Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View
by: Elizabeth A. Mills, et al.
Published: (2018-02-01)